

2019 Future of Sinusitis R&D Pipeline Drugs and Companies- Analysis of Global Sinusitis Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2CAAC2A029EEN.html>

Date: January 2019

Pages: 75

Price: US\$ 2,199.00 (Single User License)

ID: 2CAAC2A029EEN

Abstracts

The global demand for Sinusitis treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Sinusitis pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Sinusitis pipeline companies from advancing their products into Phase 3 or Phase 4.

Sinusitis Report Description

The H1 2019 pipeline review report on Sinusitis pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Sinusitis pipeline compounds.

The Sinusitis pipeline guide presents information on all active drugs currently being developed for Sinusitis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Sinusitis

pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Sinusitis drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Sinusitis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Sinusitis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Sinusitis pipeline report includes

An overview of Sinusitis disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator,

Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Sinusitis pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Sinusitis pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Sinusitis pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL SINUSITIS PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Sinusitis Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Sinusitis pipeline, H1- 2019
- 3.5 Mechanism of Action wise Sinusitis Pipeline Candidates

4. AMPLIPHI BIOSCIENCES CORP SINUSITIS PIPELINE DETAILS

- 4.1 AmpliPhi Biosciences Corp Business Profile
- 4.2 AmpliPhi Biosciences Corp Sinusitis Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. ANAPTYSBIO INC SINUSITIS PIPELINE DETAILS

- 5.1 AnaptysBio Inc Business Profile
- 5.2 AnaptysBio Inc Sinusitis Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. CRS BIO SINUSITIS PIPELINE DETAILS

- 6.1 CRS Bio Business Profile
- 6.2 CRS Bio Sinusitis Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. GLYCOMIRA THERAPEUTICS INC SINUSITIS PIPELINE DETAILS

- 7.1 GlycoMira Therapeutics Inc Business Profile
- 7.2 GlycoMira Therapeutics Inc Sinusitis Drug Details
 - 7.2.1 Drug Snapshot

- 7.2.1.1 Originator
- 7.2.1.2 Collaborator/Co-Developer
- 7.2.1.3 Route of Administration
- 7.2.1.4 Orphan Drug/Fast Track/Special Designation
- 7.2.1.5 Area
- 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. INTREXON CORP SINUSITIS PIPELINE DETAILS

- 8.1 Intrexon Corp Business Profile
- 8.2 Intrexon Corp Sinusitis Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. KNOPP BIOSCIENCES LLC SINUSITIS PIPELINE DETAILS

- 9.1 Knopp Biosciences LLC Business Profile
- 9.2 Knopp Biosciences LLC Sinusitis Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator
 - 9.2.1.2 Collaborator/Co-Developer
 - 9.2.1.3 Route of Administration
 - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 9.2.1.5 Area

- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. KYORIN PHARMACEUTICAL CO LTD SINUSITIS PIPELINE DETAILS

- 10.1 Kyorin Pharmaceutical Co Ltd Business Profile
- 10.2 Kyorin Pharmaceutical Co Ltd Sinusitis Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. KYOWA HAKKO KIRIN CO LTD SINUSITIS PIPELINE DETAILS

- 11.1 Kyowa Hakko Kirin Co Ltd Business Profile
- 11.2 Kyowa Hakko Kirin Co Ltd Sinusitis Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area
 - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

12. LYRA THERAPEUTICS SINUSITIS PIPELINE DETAILS

12.1 Lyra Therapeutics Business Profile

12.2 Lyra Therapeutics Sinusitis Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

13. MERCK & CO INC SINUSITIS PIPELINE DETAILS

13.1 Merck & Co Inc Business Profile

13.2 Merck & Co Inc Sinusitis Drug Details

13.2.1 Drug Snapshot

13.2.1.1 Originator

13.2.1.2 Collaborator/Co-Developer

13.2.1.3 Route of Administration

13.2.1.4 Orphan Drug/Fast Track/Special Designation

13.2.1.5 Area

13.2.1.6 Type of Molecular Entity

13.3 Current Status

13.4 Drug Overview

13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14. NOTA LABORATORIES LLC SINUSITIS PIPELINE DETAILS

14.1 Nota Laboratories LLC Business Profile

14.2 Nota Laboratories LLC Sinusitis Drug Details

14.2.1 Drug Snapshot

14.2.1.1 Originator

14.2.1.2 Collaborator/Co-Developer

14.2.1.3 Route of Administration

14.2.1.4 Orphan Drug/Fast Track/Special Designation

14.2.1.5 Area

14.2.1.6 Type of Molecular Entity

14.3 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15. OPTINOSE US INC SINUSITIS PIPELINE DETAILS

15.1 OptiNose US Inc Business Profile

15.2 OptiNose US Inc Sinusitis Drug Details

15.2.1 Drug Snapshot

15.2.1.1 Originator

15.2.1.2 Collaborator/Co-Developer

15.2.1.3 Route of Administration

15.2.1.4 Orphan Drug/Fast Track/Special Designation

15.2.1.5 Area

15.2.1.6 Type of Molecular Entity

15.3 Current Status

15.4 Drug Overview

15.5 Drug Mechanism of Action

15.6 Clinical/Pre-clinical Trial Details

15.7 Latest Drug Developments

16. PARATEK PHARMACEUTICALS SINUSITIS PIPELINE DETAILS

16.1 Paratek Pharmaceuticals Business Profile

16.2 Paratek Pharmaceuticals Sinusitis Drug Details

16.2.1 Drug Snapshot

16.2.1.1 Originator

16.2.1.2 Collaborator/Co-Developer

16.2.1.3 Route of Administration

- 16.2.1.4 Orphan Drug/Fast Track/Special Designation
- 16.2.1.5 Area
- 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17. PFIZER INC SINUSITIS PIPELINE DETAILS

- 17.1 Pfizer Inc Business Profile
- 17.2 Pfizer Inc Sinusitis Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. PROCLARX LLC SINUSITIS PIPELINE DETAILS

- 18.1 ProclaRx LLC Business Profile
- 18.2 ProclaRx LLC Sinusitis Drug Details
 - 18.2.1 Drug Snapshot
 - 18.2.1.1 Originator
 - 18.2.1.2 Collaborator/Co-Developer
 - 18.2.1.3 Route of Administration
 - 18.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 18.2.1.5 Area
 - 18.2.1.6 Type of Molecular Entity
- 18.3 Current Status
- 18.4 Drug Overview

- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19. ROCHE SINUSITIS PIPELINE DETAILS

- 19.1 Roche Business Profile
- 19.2 Roche Sinusitis Drug Details
 - 19.2.1 Drug Snapshot
 - 19.2.1.1 Originator
 - 19.2.1.2 Collaborator/Co-Developer
 - 19.2.1.3 Route of Administration
 - 19.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 19.2.1.5 Area
 - 19.2.1.6 Type of Molecular Entity
- 19.3 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20. THERABRON THERAPEUTICS INC SINUSITIS PIPELINE DETAILS

- 20.1 Therabron Therapeutics Inc Business Profile
- 20.2 Therabron Therapeutics Inc Sinusitis Drug Details
 - 20.2.1 Drug Snapshot
 - 20.2.1.1 Originator
 - 20.2.1.2 Collaborator/Co-Developer
 - 20.2.1.3 Route of Administration
 - 20.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 20.2.1.5 Area
 - 20.2.1.6 Type of Molecular Entity
- 20.3 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

20. LATEST SINUSITIS DRUG PIPELINE DEVELOPMENTS, 2019

21. APPENDIX

21.1 About Us

21.2 Sources and Methodology

21.3 Contact Information

I would like to order

Product name: 2019 Future of Sinusitis R&D Pipeline Drugs and Companies- Analysis of Global Sinusitis Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2CAAC2A029EEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2CAAC2A029EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

